The trial included 2,247 adolescents in the U.S. and took place between May and September 2021, a period when delta was the dominant strain. The findings showed the two-dose vaccine was 82 percent effective against infection and no safety signals were observed, Novovax said in a Feb. 10 news release.
The drugmaker in January submitted an emergency use authorization request to the FDA for its vaccine in adults. In adults, the vaccine was 90.4 percent effective at preventing infection, trial findings showed.
Novovax said it plans to submit applications to regulators for the vaccine’s use in adolescents in the first quarter of 2022.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
